Skip to main content

Advertisement

Table 1 Clinical characteristics of the clinical population relative to PCSK9 groups

From: Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina

  Clinical population n = 539 Quartile I < 138 ng/L n = 135 Quartile II–III 138–264 ng/L n = 270 Quartile IV > 264 ng/L n = 134 P value
Demographics
 Age, years 60 ± 9 61 ± 9 60 ± 9 61 ± 8 ns
 Male gender 326 (60) 88 (65) 166 (61) 72 (53) 0.1411
Clinical characteristics
 Typical angina 140 (26) 30 (22) 66 (24) 44 (33) ns
 Atypical angina 321 (60) 78 (58) 166 (61) 77 (57)
 Non-anginal chest pain 78 (14) 27 (20) 38 (14) 13 (10)
 LVEF% 60 ± 8 60 ± 9 60 ± 9 61 ± 7 ns
 Pre-test probability of CAD 48 ± 19 48 ± 18 48 ± 19 49 ± 20 ns
Cardiovascular risk factors
 Family history of CAD 189 (35) 40 (30) 90 (33) 59 (44) 0.0328
 Diabetes 160 (30) 37 (27) 90 (33) 33 (25) ns
 Hypercholesterolemia 322 (60) 77 (57) 163 (60) 82 (61) ns
 Hypertension 360 (67) 88 (65) 181 (67) 91 (68) ns
 Smoking 133 (25) 30 (22) 69 (26) 34 (25) ns
 BMI, kg/m2 27.7 ± 4.3 27.9 ± 4.0 28.0 ± 4.3 26.8 ± 4.6 0.0282
 Metabolic syndrome 185 (34) 54 (40) 100 (37) 31 (23) 0.0059
Pharmacological therapies
 Beta-blockers 215 (40) 64 (47) 105 (39) 46 (34) ns
 Calcium channel blockers 74 (14) 21 (16) 32 (12) 21 (16) ns
 ACE inhibitors 166 (31) 43 (32) 87 (32) 36 (27) ns
 ARBs 91 (17) 23 (17) 43 (16) 25 (19) ns
 Diuretics 93 (17) 27 (20) 44 (16) 22 (16) ns
 Anti-diabetic 111 (21) 27 (20) 66 (24) 18 (13) 0.0354
 Statins 279 (52) 72 (53) 148 (55) 59 (44) ns
 Aspirin 316 (59) 94 (70) 147 (54) 75 (56) 0.0107
 Anti-coagulants 11 (2) 2 (1) 5 (2) 4 (3) ns
  1. Continuous variables are presented as mean ± standard deviation, categorical variables as absolute N and (%)